Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following 'Encouraging' Data on Next Generation Selective RET Inhibitor | Illinois
CHICAGO--(BUSINESS WIRE)--Jun 5, 2023--
Stay updated with breaking news from Ellipses Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHICAGO--(BUSINESS WIRE)--Jun 5, 2023--
Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.
More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development
Ellipses Pharma founder and chairman Professor Sir Christopher Evans speaks to Proactive about his work at the cancer-focused international drug development...